Nitric oxide (NO) is an important molecule involved in a myriad of physiological functions. In pulmonary hypertensive diseases, NO production is decreased resulting in vasoconstriction and vascular remodeling. While in pulmonary inflammatory diseases, NO production is increased resulting in tissue damage. NO is generated from L-arginine (L-arg) by the NO synthases (NOS). The cellular bioavailability of L-arg to NOS is determined in large part by uptake of extracellular L-arg via the cationic amino acid transporters (CAT). Preliminary studies suggest that manipulation of L-arg uptake modifies clinically important parameters in highly vulnerable patient populations. Thus, the studies described in the present application are focused on elucidation of the functional and mechanistic aspects of endothelial cell uptake of L-arg by CAT and its role in regulation of NO production in the lung. The long-term goals of these studies are to develop therapies that increase NO production by facilitating CAT-mediated L-arg uptake in pulmonary hypertensive diseases, and that decrease NO production by inhibiting CAT-mediated L-arg uptake in inflammatory lung diseases. The working hypothesis is that NO production can be modulated by control of L-arg bioavailability to NOS through alterations in CAT-mediated L-arg transport. The studies will address the hypothesis in 3 specific aims: 1) to test the hypothesis that alterations in CAT activities regulate NO production by altering the bioavailability of L-arg to NOS;2) to test the hypothesis that Src-family tyrosine kinases and mitogen- activated protein kinases mediate inflammation-induced alterations in the expression of CAT and/or NOS; and 3) to test the hypothesis that gene transfer to regulate CAT expression in vivo will affect NO production in the lung, and thereby affect pulmonary vasomotor tone and lung injury.

Public Health Relevance

Therapies aimed at manipulating NO-mediated effects in lung diseases have centered on pharmacological inhibition of NO production or inhalation of exogenous NO, however a majority of these critically ill patients do not respond to these therapies. L-arg uptake represents a rate-limiting step in lung NO production. The present proposal will provide translational data necessary for the design of rational clinical trials to determine safe and effective pharmacological and genetic manipulations of L-arg uptake rates, and thereby NO production, in severe pulmonary diseases, such as ARDS and pulmonary hypertension.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Lung Injury, Repair, and Remodeling Study Section (LIRR)
Program Officer
Harabin, Andrea L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Nationwide Children's Hospital
United States
Zip Code
Jin, Yi; Liu, Yusen; Nelin, Leif D (2015) Extracellular signal-regulated kinase mediates expression of arginase II but not inducible nitric-oxide synthase in lipopolysaccharide-stimulated macrophages. J Biol Chem 290:2099-111
Crowell, Sara; Wancket, Lyn M; Shakibi, Yasmine et al. (2014) Post-translational regulation of mitogen-activated protein kinase phosphatase (MKP)-1 and MKP-2 in macrophages following lipopolysaccharide stimulation: the role of the C termini of the phosphatases in determining their stability. J Biol Chem 289:28753-64
Yan, Jing; Ralston, Melissa M; Meng, Xiaomei et al. (2013) Glutathione reductase is essential for host defense against bacterial infection. Free Radic Biol Med 61:320-32
Jin, Yi; Chen, Bernadette; Calvert, Thomas J et al. (2013) Chronic hypoxia decreases arterial and venous compliance in isolated perfused rat lungs: an effect that is reversed by exogenous L-arginine. Am J Physiol Heart Circ Physiol 304:H195-205
Chen, Bernadette; Calvert, Andrea E; Meng, Xiaomei et al. (2012) Pharmacologic agents elevating cAMP prevent arginase II expression and proliferation of pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 47:218-26
Matta, Ranyia; Barnard, John A; Wancket, Lyn M et al. (2012) Knockout of Mkp-1 exacerbates colitis in Il-10-deficient mice. Am J Physiol Gastrointest Liver Physiol 302:G1322-35
Yan, Jing; Meng, Xiaomei; Wancket, Lyn M et al. (2012) Glutathione reductase facilitates host defense by sustaining phagocytic oxidative burst and promoting the development of neutrophil extracellular traps. J Immunol 188:2316-27
Chicoine, Louis G; Chicione, Louis G; Stenger, Michael R et al. (2011) Nitric oxide suppression of cellular proliferation depends on cationic amino acid transporter activity in cytokine-stimulated pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol 300:L596-604
Cui, Hongmei; Chen, Bernadette; Chicoine, Louis G et al. (2011) Overexpression of cationic amino acid transporter-1 increases nitric oxide production in hypoxic human pulmonary microvascular endothelial cells. Clin Exp Pharmacol Physiol 38:796-803
Jin, Yi; Calvert, Thomas J; Chen, Bernadette et al. (2010) Mice deficient in Mkp-1 develop more severe pulmonary hypertension and greater lung protein levels of arginase in response to chronic hypoxia. Am J Physiol Heart Circ Physiol 298:H1518-28

Showing the most recent 10 out of 19 publications